A phase I/II clinical trial of a CDK1 inhibitor plus gemcitabine for pancreatic cancer revealed that this regimen not only inhibited tumor growth but also eliminated resistance to gemcitabine (10). This evidence concerns the gene CDK1 and neoplasm.